RGEN

Repligen Corp. 10-Q Summary: Period Ended September 30, 2008

Business Context and Reporting Period

This is an unaudited quarterly report (Form 10-Q) for Repligen Corporation for the three and six-month periods ended September 30, 2008. Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases and selling Protein A products for monoclonal antibody purification. The company also generates revenue through intellectual property licensing and royalties.

Key Financial Metrics

Revenue Composition (Six Months): Product revenue was $8.68 million, while Royalty and other revenue was $10.07 million. The royalty revenue was predominantly driven by a settlement with Bristol-Myers Squibb.

Material Changes vs. Prior Period

• Revenue: Total revenue for the six months ended September 30, 2008, increased 65% to $18.75 million compared to $11.33 million in the prior year period. This increase was primarily due to $9.7 million in royalty revenue recognized from the Bristol-Myers Squibb settlement. Conversely, Product revenue (Protein A) decreased 13% to $8.68 million due to lower sales volume and timing of customer orders.
• Net Income: Net income for the six months ended September 30, 2008, was $8.42 million, a significant decrease from $40.55 million in the prior year period. The prior year included a one-time net gain of $40.17 million from a litigation settlement with ImClone Systems, which did not recur in the current period.
• Operating Expenses: Research and development expenses increased 38% to $4.55 million for the six-month period, driven by increased clinical trial activity for RG1068 and RG2417. Selling, general, and administrative expenses decreased 31% to $2.98 million, largely due to reduced litigation expenses.
• Liquidity: Total cash, cash equivalents, and marketable securities increased to approximately $65.6 million as of September 30, 2008, up from $60.6 million at the end of the previous fiscal year.

Guidance, Outlook, and Risks

Outlook: Management believes current cash and investment balances are adequate to meet needs for at least the next 24 months. Future revenue is expected to be derived from Protein A sales, Bristol-Myers Squibb royalties, research grants, and interest income. Sales of SecreFlo have ceased due to the expiration of the supplier agreement.

Key Risks and Contingencies:

• Clinical Trial Success: Future capital requirements and revenue potential depend heavily on the success of clinical studies for therapeutic candidates (e.g., RG1068, RG2417, and Friedreich's Ataxia programs).
• Customer Concentration: Royalty revenue from Bristol-Myers Squibb represented 52% of total revenue for the six months ended September 30, 2008. Two largest Protein A customers accounted for 39% of total revenue for the same period.
• Regulatory and IP: Risks include obtaining regulatory approvals, maintaining intellectual property rights, and potential litigation regarding patents.
• Market Volatility: The company faces risks associated with the volatile nature of the biotechnology marketplace and the ability to secure additional financing if needed for acquisitions or development.

Investor Verification Checklist

• Bristol-Myers Squibb Royalties: Verify the sustainability of royalty revenue from Orencia sales and the specific terms of the settlement agreement (1.8% to 4% royalty rates).
• Protein A Sales Trends: Assess the volatility of Protein A sales volume and the impact of large-scale customer order timing on quarterly results.
• Clinical Trial Progress: Monitor enrollment and results for Phase 3 trial RG1068 (secretin) and Phase 2b trial RG2417 (uridine), as these drive significant R&D spend.
• Cash Burn Rate: Confirm that the $65.6 million cash position remains sufficient given the increased R&D spending and the cessation of SecreFlo sales.
• Stock Repurchase Program: Note the active repurchase program (1.25 million shares authorized); 75,441 shares were repurchased in the quarter.